how to use kisspeptin: Frequently asked questions

Administering kisspeptin before adequate estradiol priming produces minimal GnRH release because GPR54 receptor expression in the hypothalamus is estradiol-dependent. Without sufficient estradiol, kisspeptin binds to fewer receptors and fails to generate the sustained GnRH pulse train required for an LH surge. The result is either a blunted LH response (peak levels 30–50% of expected) or no response at all. This is not a safety issue. It is a failed intervention. The peptide is metabolised without effect, and you have wasted the dose. Correct timing requires monitoring estradiol levels (target ≥200 pg/mL) and ultrasound confirmation of a mature follicle (≥16 mm) before administering kisspeptin. Early administration is a common error in IVF research protocols where investigators attempt to synchronise multiple subjects to a fixed schedule rather than individualising timing to each subject's follicular maturation.

Discard it immediately. Cloudiness, discoloration, or visible particulates indicate protein aggregation or contamination. Neither is reversible, and injecting degraded peptide is ineffective at best and potentially irritating to tissue at worst. Kisspeptin should appear as a clear, colorless solution after reconstitution. Degradation is most commonly caused by temperature excursions during shipping, improper storage, or introducing air pressure into the vial during draws. If this happens with a newly reconstituted vial, contact the supplier. If it happens after several days of use, review your storage and draw technique.

Allow at least 72 hours between kisspeptin doses to prevent GPR54 receptor tachyphylaxis. While kisspeptin doesn't cause the sustained receptor downregulation seen with continuous GnRH agonists, repeated daily dosing can reduce peak LH response by 30-40% as GPR54 receptors become transiently refractory. If multiple administrations are required for longitudinal HPG axis monitoring, alternate-day dosing maintains full receptor sensitivity. Protocols using kisspeptin for repeated ovulation induction (as in assisted reproduction contexts) typically administer once per cycle at the intended ovulation trigger point. Not continuously.

Receptor desensitisation manifests as diminishing LH response despite consistent dosing. Week 1 produces a 5× LH spike, week 3 produces only 2×. This happens when kisspeptin is administered too frequently or at too high a dose, overwhelming GPR54 receptor recycling capacity. The fix: cycle off kisspeptin for 7–10 days to allow receptor resensitisation, then resume at a lower dose (50–100mcg). Alternatively, switch to an every-other-day dosing schedule to maintain pulsatility without constant receptor occupation.

Discard the vial immediately. Do not inject it. Cloudiness or particulate matter indicates protein aggregation, bacterial contamination, or incomplete dissolution. Kisspeptin in solution should be perfectly clear and colourless. Aggregated peptides have altered three-dimensional structure and will not bind GPR54 receptors effectively, rendering the injection useless. Contaminated solutions pose infection risk at the injection site or systemically. If cloudiness appears in a vial that was previously clear, a temperature excursion likely occurred. Check your refrigerator's actual temperature with a standalone thermometer, as many household refrigerators fluctuate between 4–10°C rather than maintaining the required 2–8°C range consistently.

Recheck baseline LH levels. If LH remains suppressed (<1.5 IU/L) after 14 days of daily kisspeptin dosing, the issue is likely hypothalamic resistance or incorrect dosing. Increase the dose to 250–500mcg and retest LH 90 minutes post-injection. If LH rises but testosterone doesn't, the problem is primary testicular insufficiency. The testes aren't responding to LH signals, and kisspeptin won't resolve that. Consider adding MK 677 to support overall anabolic signalling while investigating the root cause.

Inject the missed dose as soon as you remember, then resume the regular schedule. But do not double-dose to compensate. Missing a single injection disrupts the pulsatile pattern temporarily but does not reset progress if corrected within 12 hours. If you consistently miss doses (three or more per week), the protocol effectiveness drops significantly because GPR54 receptor sensitivity depends on predictable pulse timing. Set alarms for both injection windows and treat them as non-negotiable appointments.

Kisspeptin response may be blunted if prior GnRH agonist exposure caused pituitary gonadotroph desensitisation. GnRH receptor downregulation at the pituitary level doesn't recover immediately after agonist withdrawal. Full sensitivity restoration takes 8-12 weeks. In subjects with recent GnRH agonist history, expect 20-40% lower LH responses to kisspeptin compared to agonist-naive subjects. This doesn't mean kisspeptin failed to stimulate GnRH release; it means the pituitary gonadotrophs downstream are still recovering their responsiveness to GnRH signalling. Serial kisspeptin challenges spaced 4-6 weeks apart can track pituitary recovery progression.

Normal or elevated LH (>5 IU/L) with low testosterone indicates primary testicular failure. The testes aren't converting LH signals into testosterone production. Kisspeptin won't help because the problem isn't upstream signalling; it's downstream enzymatic function in Leydig cells. Investigate potential causes: testicular atrophy from prior anabolic use, varicocele, chronic inflammation, or genetic conditions affecting steroidogenesis enzymes. In this scenario, exogenous testosterone replacement is the more appropriate intervention.

First, verify the dose calculation and confirm that estradiol priming was adequate before administration. A blunted or absent LH response typically indicates one of three scenarios: (1) the kisspeptin dose was too low to saturate GPR54 receptors, (2) estradiol levels were below the 200 pg/mL threshold needed to sensitise GnRH neurons, or (3) the peptide was degraded before injection due to improper storage. Measure serum LH at 6, 12, and 24 hours post-injection. Some subjects exhibit delayed but sustained LH elevation rather than the typical sharp peak. If LH remains baseline at all three timepoints, the protocol failed. Reassess follicular development via ultrasound and estradiol levels, then consider repeating the injection 48–72 hours later at a higher dose (e.g., escalate from 3.2 to 6.4 nmol/kg) if conditions are appropriate.

This indicates that the kisspeptin mechanism is working (GnRH → LH pathway is intact) but the issue lies downstream. Check free testosterone, not just total testosterone. SHBG elevation can keep free testosterone suppressed even as total levels rise. If free testosterone is normal but libido remains low, the problem may be androgen receptor sensitivity, vascular health (poor blood flow to erectile tissue), or psychological factors that kisspeptin cannot address. Consider nitric oxide precursors like L-citrulline (6–8g daily) to improve vascular response, or consult an endocrinologist to rule out receptor-level dysfunction.

Check three variables: peptide storage temperature (must remain 2-8°C post-reconstitution), injection timing relative to menstrual phase (GPR54 sensitivity lowest during luteal phase), and subject's baseline HPG axis function (kisspeptin cannot stimulate GnRH neurons that are absent or permanently suppressed). The absence of LH response to kisspeptin is diagnostically significant. It suggests either hypothalamic GnRH neuron dysfunction (as in congenital hypogonadotropic hypogonadism) or complete receptor desensitisation from prior continuous GnRH analog exposure. Standard GnRH stimulation tests bypass the hypothalamus entirely and can miss this distinction. Kisspeptin non-response specifically localises the defect to the GPR54-GnRH neuron pathway.